NAROPEINE 5 mg/ml, solution for injection 5 ampoules of 10 ml
Active ingredients: Ropivacaine hydrochloride, (S)-N-(2,6-dimethylphenyl)-1-ethylpiperidine-2-carboxamide
Commercialized according to BDPMDispensing in France: Prescription only, hospital use
Solution for injection5 ampoules of 10 mlintrathécale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- NAROPEINE 5 mg/ml, solution injectable
- Pharmaceutical form
- solution injectable
- Route of administration
- intrathécale
- Presentation description
- 5 ampoule(s) polypropylène de 10 ml
- Marketing authorisation holder
- ASPEN PHARMA TRADING (IRLANDE)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 28 Feb 2025
- Prescription and dispensing conditions
- Prescription only, hospital use
- List II: prescription-only medicine
- Hospital use only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
66101975CIP75654982CIP133400956549825Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CHLORHYDRATE DE ROPIVACAÏNE MONOHYDRATÉsolution | 5,29 mg · 1 ml | SA |
| CHLORHYDRATE DE ROPIVACAÏNE ANHYDREsolution | 5 mg · 1 ml | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.